SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cel-Sci Corp (AMEX:CVM) (was HIV)
CVM 5.830-9.0%Jan 23 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Tom Shutters who wrote (2729)10/27/1999 9:03:00 AM
From: Tom Shutters   of 2836
 
"Interleukin-2 acutely activates CD8+ T cells in HIV-positive patients"

..."This [study] shows that, despite the functional abnormalities of CD8+ T lymphocytes previously reported in HIV-infected patients, these cells remain fully sensitive to the stimulating effect of IL-2," the researchers conclude."

"IL-2 treatment, they add, may play a key role in exhausting the HIV reservoir and thus "...may improve long-term control of HIV infection."

ama-assn.org

"Researchers close to AIDS vaccine"

afr.com.au
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News